Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
Jul 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
Sep 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
Sep 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
Management of myelodysplastic syndromes after failure of response to hypomethylating agents |
May 2019 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
Apr 2019 |
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia |
Jul 2023 |
Annals of Hematology |
Aplastic Anemia |
Modified Delphi Panel Consensus Recommendations for Management of Severe Aplastic Anemia |
Apr 2024 |
Blood Advances |
Aplastic Anemia |